Table 2.
Multiple linear regression models displaying adjusted estimates for lnFGF19 for outcomes of arteriosclerosis parameters adjusted for the other clinical covariates in each model in patients with T2D
| Models | B (95% CI) | β | t | p | R2 for model |
|---|---|---|---|---|---|
| baPWV | |||||
| Model 0: unadjusted | − 167.6 (− 227.0 to − 108.3) | − 0.37 | − 5.57 | < 0.001 | 0.135 |
| Model 1: age, sex, BMI and duration | − 161.8 (− 218.7 to − 104.9) | − 0.36 | − 5.61 | < 0.001 | 0.241 |
| Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, TG, HDLC, LDLC, and Lpa | − 98.7 (− 171.5 to − 26.0) | − 0.22 | − 2.70 | 0.008 | 0.587 |
| Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments | − 86.8 (− 164.5 to − 9.1) | − 0.20 | − 2.23 | 0.029 | 0.599 |
| lnAIP | |||||
| Model 0: unadjusted | − 0.22 (− 0.32 to − 0.12) | − 0.30 | − 4.46 | < 0.001 | 0.091 |
| Model 1: age, gender, BMI and diabetic duration | − 0.21 (− 0.30 to − 0.11) | − 0.28 | − 4.19 | < 0.001 | 0.145 |
| Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, LDLC and Lpa | − 0.21 (− 0.35 to − 0.07) | − 0.29 | − 3.03 | 0.003 | 0.342 |
| Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments | − 0.21 (− 0.36 to − 0.05) | − 0.28 | − 2.66 | 0.010 | 0.491 |